Cynata Therapeutics Limited (CYYNF)
USD 0.19
(0.0%)
USD 0.19
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -280.73 Thousand AUD | -120.43% |
| 2023 | 1.37 Million AUD | -81.65% |
| 2022 | 7.49 Million AUD | 491.62% |
| 2021 | 1.26 Million AUD | -81.19% |
| 2020 | 6.73 Million AUD | 554.38% |
| 2019 | 1.02 Million AUD | -6.08% |
| 2018 | 1.09 Million AUD | -25.44% |
| 2017 | 1.46 Million AUD | 79.36% |
| 2016 | 818.98 Thousand AUD | 186.77% |
| 2015 | 285.58 Thousand AUD | 1039.69% |
| 2014 | 25.05 Thousand AUD | -0.86% |
| 2013 | 25.27 Thousand AUD | 107.04% |
| 2012 | -359.02 Thousand AUD | -115.63% |
| 2011 | -166.49 Thousand AUD | 26.31% |
| 2010 | -225.95 Thousand AUD | -2131.44% |
| 2009 | -10.12 Thousand AUD | -150.69% |
| 2008 | 19.97 Thousand AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q4 | -140.36 Thousand AUD | 0.0% |
| 2024 Q1 | 1.27 Million AUD | 696.66% |
| 2024 Q2 | 1.13 Million AUD | -11.03% |
| 2024 FY | -280.73 Thousand AUD | -120.43% |
| 2023 FY | 1.37 Million AUD | -81.65% |
| 2023 Q1 | 900.5 Thousand AUD | 246.62% |
| 2023 Q3 | -73.34 Thousand AUD | -109.64% |
| 2023 Q4 | -213.32 Thousand AUD | -190.85% |
| 2023 Q2 | 760.51 Thousand AUD | -15.54% |
| 2022 Q3 | 399.77 Thousand AUD | -88.05% |
| 2022 Q2 | 3.34 Million AUD | -4.02% |
| 2022 FY | 7.49 Million AUD | 491.62% |
| 2022 Q1 | 3.48 Million AUD | 462.8% |
| 2022 Q4 | 259.79 Thousand AUD | -35.02% |
| 2021 Q2 | -126.23 Thousand AUD | -1018.35% |
| 2021 Q1 | 13.74 Thousand AUD | -98.79% |
| 2021 FY | 1.26 Million AUD | -81.19% |
| 2021 Q3 | 759.28 Thousand AUD | 701.47% |
| 2021 Q4 | 619.29 Thousand AUD | -18.44% |
| 2020 Q4 | 1.14 Million AUD | -10.96% |
| 2020 Q1 | 2.22 Million AUD | 1687.94% |
| 2020 FY | 6.73 Million AUD | 554.38% |
| 2020 Q2 | 2.08 Million AUD | -6.31% |
| 2020 Q3 | 1.28 Million AUD | -38.55% |
| 2019 Q1 | 654.4 Thousand AUD | 1796.66% |
| 2019 Q2 | 654.4 Thousand AUD | 0.0% |
| 2019 FY | 1.02 Million AUD | -6.08% |
| 2019 Q4 | -140.1 Thousand AUD | -111985.6% |
| 2019 Q3 | -125.00 AUD | -100.02% |
| 2018 Q4 | -38.57 Thousand AUD | 0.0% |
| 2018 Q2 | 726.13 Thousand AUD | -0.0% |
| 2018 Q1 | 726.13 Thousand AUD | 5818.07% |
| 2018 FY | 1.09 Million AUD | -25.44% |
| 2018 Q3 | -38.57 Thousand AUD | -105.31% |
| 2017 Q4 | -12.69 Thousand AUD | 0.0% |
| 2017 FY | 1.46 Million AUD | 79.36% |
| 2017 Q1 | 887.13 Thousand AUD | 1931.45% |
| 2017 Q3 | -12.69 Thousand AUD | -101.43% |
| 2017 Q2 | 887.13 Thousand AUD | 0.0% |
| 2016 FY | 818.98 Thousand AUD | 186.77% |
| 2016 Q2 | 506.18 Thousand AUD | -0.0% |
| 2016 Q1 | 506.18 Thousand AUD | 317.94% |
| 2016 Q4 | 43.67 Thousand AUD | 0.0% |
| 2016 Q3 | 43.67 Thousand AUD | -91.37% |
| 2015 Q3 | 121.11 Thousand AUD | 458.73% |
| 2015 Q4 | 121.11 Thousand AUD | 0.0% |
| 2015 Q2 | 21.67 Thousand AUD | 0.0% |
| 2015 Q1 | 21.67 Thousand AUD | 0.0% |
| 2015 FY | 285.58 Thousand AUD | 1039.69% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 Q3 | - AUD | -100.0% |
| 2014 Q2 | 12.52 Thousand AUD | 0.0% |
| 2014 Q1 | 12.52 Thousand AUD | 0.0% |
| 2014 FY | 25.05 Thousand AUD | -0.86% |
| 2013 Q4 | - AUD | 0.0% |
| 2013 FY | 25.27 Thousand AUD | 107.04% |
| 2013 Q3 | - AUD | 0.0% |
| 2012 FY | -359.02 Thousand AUD | -115.63% |
| 2011 FY | -166.49 Thousand AUD | 26.31% |
| 2010 FY | -225.95 Thousand AUD | -2131.44% |
| 2009 FY | -10.12 Thousand AUD | -150.69% |
| 2008 FY | 19.97 Thousand AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 465.722% |
| CSL Limited | 7.56 Billion USD | 100.004% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 101.872% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 9150.032% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 102.398% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.236% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -722.056% |
| Mesoblast Limited | -35.16 Million USD | 99.202% |
| Marizyme, Inc. | 457.7 Thousand USD | 161.335% |
| Genus plc | 178.7 Million USD | 100.157% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 168.444% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -2452.109% |
| ContraFect Corporation | -154 Thousand USD | -82.294% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -461.464% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -962.29 Thousand USD | 70.827% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 27.553% |
| MultiCell Technologies, Inc. | 49.32 USD | 569305.191% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.697% |
| EV Biologics, Inc. | 48.9 Thousand USD | 674.094% |
| Q BioMed Inc. | -8988.00 USD | -3023.409% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.994% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -1720.099% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 501.046% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -125.939% |
| SQZ Biotechnologies Company | 9.79 Million USD | 102.866% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -5569.063% |
| Arch Therapeutics, Inc. | -2439.00 USD | -11410.127% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 527.112% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 299.809% |
| Neon Bloom, Inc. | - USD | Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.128% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 551.149% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -187.886% |
| GB Sciences, Inc. | -624.00 USD | -44889.103% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -226.326% |
| argenx SE | 1.1 Billion USD | 100.025% |
| HST Global, Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -134867.308% |
| Enzolytics Inc. | 30.7 Thousand USD | 1014.198% |
| Resverlogix Corp. | - USD | Infinity% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 158.191% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 98.912% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.633% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 75.408% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 45.437% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 145.471% |
| ONE Bio Corp. | 20.12 Million USD | 101.395% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.069% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -3069.964% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -234.807% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Agentix Corp. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 55.449% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 128.415% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 102.921% |
| BioStem Technologies, Inc. | 15.42 Million USD | 101.82% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -2272.049% |
| Cell Source, Inc. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -481.719% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 259.001% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 259.001% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 120.686% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -868.041% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Qrons Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 162.379% |
| SYBLEU INC | 11.69 Thousand USD | 2500.239% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 12.136% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 106.092% |
| Bioxytran, Inc. | -8285.00 USD | -3288.437% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 24.737% |
| Neutra Corp. | 14.33 Thousand USD | 2058.368% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -242.356% |
| PureTech Health plc | -1.6 Million USD | 82.487% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 71.961% |
| IXICO plc | 3.27 Million USD | 108.585% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 59.549% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 84.325% |
| CSL Limited | 7.7 Billion USD | 100.004% |
| Cellectis S.A. | 18 Thousand USD | 1659.622% |